APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.26689/APM.v11i7.15562ArticleExploring the Potential Mechanism of Buyang Huanwu Decoction Regulating Ferroptosis to Intervene in Secondary Brain Injury After Intracerebral Hemorrhage Based on Network Pharmacology and Molecular Dockinghttps://artdesignp.com/journal/APM/11/7/10.26689/APM.v11i7.15562HuNa,ShenJunyi,AnRan,AnLiping,WangWei,ZhangLihong20261172026-07-26 Intracerebral hemorrhage (ICH) is a serious type of acute stroke that can be very harmful to people. Secondary brain injury (SBI) is associated with a poor prognosis in isolated cerebral hemorrhage (ICH), and one of the reasons for this is iron-dependent ferroptosis. Buyang Huanwu Decoction (BYHWD) is an old Chinese medicine formula for qi-deficiency-blood-stasis stroke that has been applied in the rehabilitation of ICH, but its anti-ferroptosis mechanism is not yet known. Network pharmacology and molecular docking were used to identify the active compounds, the main targets, and the pathways of BYHWD against ICH-induced ferroptosis, etc. TCMSP was used to obtain the active compounds and their corresponding targets, and the ICH- and ferroptosis-related targets were obtained from GeneCards, OMIM, and DisGeNET. PPI, GO/KEGG enrichment analysis, and molecular docking were conducted. A total of 23 are active compounds, and 87 are general targets. AKT1, TP53, IL6, and TNF were the hub genes. Thus, BYHWD will disturb neuronal iron homeostasis, lipid peroxidation, oxidative stress, and neuroinflammation by affecting the PI3K-AKT pathway. Quercetin, Kaempferol, and Luteolin can all bind to GPX4, SLC7A11, and ACSL4. BYHWD can reduce post-ICH SBI by inhibiting neuronal ferroptosis through the following targets and pathways and is therefore a good drug for this disease.Buyang Huanwu Decoction,Intracerebral haemorrhage,Secondary brain injury,Ferroptosis,Network pharmacology,Molecular docking,Neuroprotection

[1] Wang Y, Zhang L, Liu H, et al., 2024, Global Epidemiology of Intracerebral Hemorrhage: Incidence, Mortality, and Risk Factors Update 2021–2025. Journal of Stroke and Cerebrovascular Diseases, 33(5): 107892. [2] Li J, Chen X, Wang H, et al., 2023, Mechanisms of Secondary Brain Injury After Intracerebral Hemorrhage: An Updated Review. Frontiers in Neurology, 14: 1129876. [3] Dixon S, 2022, Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell Death & Differentiation, 29(1): 1–18. [4] Liu P, Xu Y, Zhang Q, et al., 2024, Ferroptosis Is a Critical Driver of Neuronal Damage After Intracerebral Hemorrhage. Brain Research Bulletin, 209: 89–98. [5] Chen L, Wang Z, Li Y, et al., 2023, Targeting Ferroptosis for the Treatment of Intracerebral Hemorrhage: Progress and Perspectives. Pharmacological Research, 192: 106895. [6] Zhao X, Yu J, 2023, Research Progress of Traditional Chinese Medicine in Intervening Secondary Brain Injury After Intracerebral Hemorrhage. Chinese Journal of Integrative Medicine, 29(7): 558–565. [7] Zhao F, Yang H, Zhu Y, et al., 2024, Buyang Huanwu Decoction Regulates Ferroptosis to Improve Ischemic Stroke Injury via Multiple Signaling Pathways. Journal of Traditional Chinese Medicine, 44(2): 211–218. [8] Zhao C, 2023, Clinical Efficacy of Modified Buyang Huanwu Decoction in the Treatment of Intracerebral Hemorrhage Sequelae and Its Effect on Neurological Function. Journal of Chinese Medicinal Materials, 46(9): 2234–2237. [9] Xing M, Song C, Meng Y, et al., 2024, Buyang Huanwu Decoction Alleviates Cerebral Injury by Inhibiting Ferroptosis via NCOA4/FTH1 Signaling Pathway. Hebei Medical Journal, 36(3): 321–325. [10] Bao Z, Zhang Y, Li H, et al., 2023, Ferroptosis in Intracerebral Hemorrhage: Mechanisms and Therapeutic Targets. Biomedicine & Pharmacotherapy, 162: 114689.